Aeglea BioTherapeutics Investor Presentation Deck
March 2023, 39 slides
  1. Aeglea BioTherapeutics
  2. Related Decks
  3. Investor Presentation Decks
redefining the possible human enzyme therapies for people with rare diseases a | Aeglea BioTherapeutics
forward looking statements | Aeglea BioTherapeutics
| Aeglea BioTherapeutics
redefining the possible with human enzyme therapies | Aeglea BioTherapeutics
human enzyme therapies for rare metabolic diseases peerless shee | Aeglea BioTherapeutics
highlights and upcoming milestones | Aeglea BioTherapeutics
potential best in class treatment for | Aeglea BioTherapeutics
classical a rare metabolic disorder with serious and potentially deadly complications classical | Aeglea BioTherapeutics
patients with classical live with both disease and treatment burden | Aeglea BioTherapeutics
classical a sizeable patient population at serious risk of severe complications | Aeglea BioTherapeutics
an innovative enzyme approach to lowering | Aeglea BioTherapeutics
treatment resulted in dose dependent response and statistically significant lowering of in mouse model | Aeglea BioTherapeutics
preclinical data support once weekly dosing of | Aeglea BioTherapeutics
phase clinical trial to generate proof of concept and path to pivotal trial | Aeglea BioTherapeutics
advancing a potential best in class therapy for classical patients | Aeglea BioTherapeutics
for deficiency | Aeglea BioTherapeutics
deficiency disease overview | Aeglea BioTherapeutics
program overview | Aeglea BioTherapeutics
peace phase trial marked and sustained reduction in plasma arginine | Aeglea BioTherapeutics
peace phase trial mobility assessed by and | Aeglea BioTherapeutics
peace phase patient level outcomes impact of across efficacy | Aeglea BioTherapeutics
peace phase safety profile | Aeglea BioTherapeutics
regulatory and program status | Aeglea BioTherapeutics
summary | Aeglea BioTherapeutics
highlights and upcoming milestones | Aeglea BioTherapeutics
financial summary | Aeglea BioTherapeutics
| Aeglea BioTherapeutics
metabolism mechanism of action | Aeglea BioTherapeutics
increased mortality and high risk of severe complications | Aeglea BioTherapeutics
| Aeglea BioTherapeutics
peace demographics | Aeglea BioTherapeutics
peace clinical characteristics | Aeglea BioTherapeutics
significantly and reduces plasma arginine levels in phase | Aeglea BioTherapeutics
mobility assessments capture potential clinical benefit of in phase trial a sunes | Aeglea BioTherapeutics
improvements in mobility measures sustained over time in phase and a mean change from aes | Aeglea BioTherapeutics
measuring the functional impact of spasticity in | Aeglea BioTherapeutics
peace phase study design | Aeglea BioTherapeutics
patient level outcomes mobility in select patients | Aeglea BioTherapeutics
attractive commercial opportunity and a targeted launch plan | Aeglea BioTherapeutics
See More
Aeglea BioTherapeutics
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Plasma
Mobility
Clinical trial
Rare disease
Recent decks by Aeglea BioTherapeutics
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
See all presentations by Aeglea BioTherapeutics (14 decks)
Related decks
NeuroBo Pharmaceuticals
Investor Presentation
December 2023
Genprex
Investor Presentation
October 2022
argenx SE
Results
October 2022
Xeris Biopharma
Investor Presentation
October 2022
AstraZeneca
Investor Day
September 2022
Genelux
Investor Presentation
February 2024
uBiome
Start Up
June 2017
Invitae
Results
August 2023
Recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
NeuroBo Pharmaceuticals
Investor Presentation
December 2023
Genprex
Investor Presentation
October 2022
argenx SE
Results
October 2022
Xeris Biopharma
Investor Presentation
October 2022
AstraZeneca
Investor Day
September 2022
Genelux
Investor Presentation
February 2024
uBiome
Start Up
June 2017
Invitae
Results
August 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io